Literature DB >> 661362

Myocardial protection during ischemic cardiac arrest. Possible deleterious effects of glucose and mannitol in coronary infusates.

D J Hearse, D A Stewart, M V Braimbridge.   

Abstract

Cardioplegic protective infusates are designed to induce rapid diastolic arrest and also to reduce or delay the onset of ischemic damage. As this study shows, the use of such infusates can greatly improve postischemic recovery of cardiac function. A number of investigators include glucose, insulin, or mannitol in their infusates in an attempt to increase the amount of protection afforded to the ischemic myocardium. Using an isolated, working rat heart model of cardiopulmonary bypass and ischemic cardiac arrest, we have shown that under certain conditions these additives can be deterimental to tissue protection. The deleterious effects of glucose and mannitol are dose dependent and can be modified by the inclusion of insulin in the infusate. The damaging effects of glucose appear to be both osmotic and metabolic in origin and those of mannitol, purely osmotic. The effects of insulin are complex and may affect a number of cellular processes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 661362

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

1.  Myocardial protection: the rebirth of potassium-based cardioplegia.

Authors:  M S Shiroishi
Journal:  Tex Heart Inst J       Date:  1999

2.  High glucose protects embryonic cardiac cells against simulated ischemia.

Authors:  Vassiliki Malliopoulou; Christodoulos Xinaris; Iordanis Mourouzis; Alexandros D Cokkinos; Nikolaos Katsilambros; Constantinos Pantos; Elissavet Kardami; Dennis V Cokkinos
Journal:  Mol Cell Biochem       Date:  2006-03-16       Impact factor: 3.396

3.  Long-term hypothermic preservation of cardiac myocytes isolated from the neonatal rat ventricle: a comparison of various crystalloid solutions.

Authors:  H Orita; M Fukasawa; H Uchino; T Uchida; S Shiono; M Washio
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

4.  Effects of calcium in continuous cardioplegia on myocardial protection.

Authors:  N Takemoto; H Kuroda; Y Nakamura; T Ichiba; N Matsuda; Y Ashida; T Hamasaki; Y Hara; S Ishiguro; T Mori
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

5.  The addition of glutathione (YM737) to a crystalloid cardioplegic solution enhances myocardial protection.

Authors:  H Okada; H Tsuboi; K Esato
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

Review 6.  Myocardial protection during cardioplegia in open-heart surgery: a review.

Authors:  R R Chatrath; T K Kaul; D R Walker
Journal:  Can Anaesth Soc J       Date:  1980-07

Review 7.  Glucose and glycogen utilisation in myocardial ischemia--changes in metabolism and consequences for the myocyte.

Authors:  L M King; L H Opie
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

8.  Heart glycogen content and isoprenaline-induced myocardial lesions.

Authors:  M Mráz; S Hynie
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

Review 9.  Metabolic intervention to affect myocardial recovery following ischemia.

Authors:  M K Pasque; A S Wechsler
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

10.  Comparison of high glucose concentration blood and crystalloid cardioplegia in paediatric cardiac surgery: a randomized clinical trial.

Authors:  Branko Mimic; Slobodan Ilic; Irena Vulicevic; Vladimir Milovanovic; Danijela Tomic; Ana Mimic; Sanja Stankovic; Tatjana Zecevic; Ben Davies; Miroslav Djordjevic
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-01-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.